This Shocking Industry Set to Become a Massive $400 Billion Market
It's worth next to nothing today… But soon, this burgeoning industry could blossom into a massive $400 billion market. That's the kind of ground floor opportunity that only comes along once in a generation.

NYSE:ZTS - Zoetis Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $184.25
  • Forecasted Upside: -1.00 %
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.5 (-0.27%)

This chart shows the closing price for ZTS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zoetis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZTS

Analyst Price Target is $184.25
▼ -1.00% Downside Potential
This price target is based on 13 analysts offering 12 month price targets for Zoetis in the last 3 months. The average price target is $184.25, with a high forecast of $208.00 and a low forecast of $160.00. The average price target represents a -1.00% upside from the last price of $186.12.

This chart shows the closing price for ZTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
This Shocking Industry Set to Become a Massive $400 Billion Market
It's worth next to nothing today… But soon, this burgeoning industry could blossom into a massive $400 billion market. That's the kind of ground floor opportunity that only comes along once in a generation.

Current Consensus is Buy

The current consensus among 13 polled investment analysts is to buy stock in Zoetis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 10 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 1 strong buy ratings
  • 10 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/28/2021ArgusBoost Price TargetBuy$185.00 ➝ $195.00Medium
5/12/2021CitigroupBoost Price Target$175.00 ➝ $184.00Medium
5/12/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price TargetNeutral$175.00 ➝ $184.00Low
5/7/2021Raymond JamesBoost Price TargetOutperform$166.00 ➝ $192.00Medium
5/7/2021BarclaysBoost Price TargetOverweight$200.00 ➝ $208.00Medium
3/8/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$166.00Medium
3/8/2021Bank of AmericaUpgradeNeutral ➝ Buy$180.00Medium
2/17/2021Credit Suisse GroupBoost Price Target$197.00 ➝ $203.00Low
11/13/2020Morgan StanleyBoost Price TargetEqual Weight$167.00 ➝ $174.00Low
11/12/2020TruistBoost Price Target$160.00 ➝ $170.00Low
11/6/2020BarclaysBoost Price TargetOverweight$175.00 ➝ $189.00Medium
9/21/2020Atlantic SecuritiesInitiated CoverageOverweight$191.00Low
8/20/2020Morgan StanleyBoost Price TargetNeutral ➝ Equal Weight$125.00 ➝ $167.00Low
8/14/2020Edward JonesUpgradeHold ➝ BuyLow
8/12/2020G.ResearchDowngradeBuy ➝ HoldLow
8/12/2020GabelliDowngradeBuy ➝ HoldLow
8/10/2020Truist FinancialBoost Price TargetNeutral ➝ Hold$112.00 ➝ $160.00Low
8/10/2020CitigroupBoost Price TargetNeutral$146.00 ➝ $160.00Low
8/7/2020Stifel NicolausBoost Price TargetTop Pick ➝ Buy$155.00 ➝ $170.00Medium
7/30/2020CitigroupBoost Price TargetNeutral$131.00 ➝ $146.00Medium
7/20/2020Bank of AmericaBoost Price TargetNeutral$135.00 ➝ $150.00Medium
6/3/2020ArgusReiterated RatingBuyLow
5/27/2020Jefferies Financial GroupInitiated CoverageBuy$152.00High
5/18/2020Credit Suisse GroupReiterated RatingBuy$147.00High
5/8/2020UBS GroupLower Price TargetNeutral$146.00 ➝ $126.00Low
5/8/2020CitigroupLower Price TargetNeutral$139.00 ➝ $131.00Low
5/7/2020BarclaysBoost Price TargetOverweight$129.00 ➝ $140.00Medium
4/2/2020Morgan StanleyLower Price TargetEqual Weight$148.00 ➝ $125.00High
3/31/2020G.ResearchUpgradeHold ➝ BuyHigh
2/28/2020The Goldman Sachs GroupReiterated RatingBuy$162.00High
2/19/2020UBS GroupBoost Price TargetNeutral$126.00 ➝ $146.00Low
2/14/2020Morgan StanleyBoost Price TargetEqual Weight$136.00 ➝ $148.00Low
2/14/2020SunTrust BanksReiterated RatingHold$145.00Low
2/13/2020CfraUpgradeBuy ➝ Strong-Buy$147.00 ➝ $160.00Low
2/12/2020Bank of AmericaReiterated RatingHold$145.00Medium
1/9/2020Raymond JamesInitiated CoverageMarket PerformLow
12/5/2019Bank of AmericaReiterated RatingHold$125.00Low
10/11/2019Credit Suisse GroupSet Price TargetBuy$138.00Low
9/30/2019Morgan StanleyBoost Price TargetHold ➝ Equal Weight$100.00 ➝ $136.00Low
9/13/2019Stifel NicolausSet Price TargetBuy$140.00Medium
9/11/2019Credit Suisse GroupReiterated RatingBuy$130.00High
9/9/2019The Goldman Sachs GroupInitiated CoverageConviction-Buy$145.00Medium
9/4/2019ArgusSet Price TargetBuy$140.00Low
8/13/2019SunTrust BanksBoost Price TargetHold$120.00 ➝ $130.00Low
8/7/2019Craig HallumBoost Price TargetBuy$132.00 ➝ $138.00Low
8/7/2019BarclaysBoost Price TargetOverweight$120.00 ➝ $135.00Low
7/22/2019Stifel NicolausBoost Price TargetBuy$110.00 ➝ $130.00Medium
7/1/2019Bank of AmericaDowngradeBuy ➝ Neutral$111.00 ➝ $120.00Low
6/25/2019Craig HallumBoost Price TargetBuy$114.00 ➝ $132.00Low
6/12/2019Cantor FitzgeraldReiterated RatingOverweight$116.00 ➝ $130.00Low
6/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$120.00Low
5/23/2019GuggenheimInitiated CoverageBuy ➝ Buy$114.00Low
5/9/2019BMO Capital MarketsBoost Price TargetMarket Perform$101.00 ➝ $105.00Low
5/2/2019GabelliDowngradeBuy ➝ Hold$108.00Low
4/2/2019Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$102.00 ➝ $112.00Low
3/20/2019UBS GroupInitiated CoverageNeutralLow
3/19/2019SunTrust BanksInitiated CoverageHold ➝ Hold$100.00Low
3/4/2019Stifel NicolausUpgradeHold ➝ Buy$97.00 ➝ $110.00Medium
2/25/2019BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$93.00 ➝ $101.00Low
1/23/2019UBS GroupInitiated CoverageNeutral ➝ Neutral$86.00Low
11/13/2018ArgusSet Price TargetBuy$105.00Medium
11/12/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Neutral$93.00Low
11/11/2018BMO Capital MarketsReiterated RatingHoldLow
11/2/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$100.00 ➝ $101.00Low
11/2/2018Morgan StanleySet Price TargetHold$100.00Low
10/17/2018Cantor FitzgeraldReiterated RatingOverweight$98.00 ➝ $105.00Low
10/15/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$100.00Medium
10/1/2018Cantor FitzgeraldReiterated RatingBuy$98.00Low
8/21/2018Stifel NicolausDowngradeBuy ➝ Hold$95.00High
8/14/2018ArgusBoost Price TargetBuy ➝ Buy$90.00 ➝ $103.00Low
8/3/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$86.00 ➝ $95.00Low
8/3/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Hold$87.00 ➝ $92.00Low
8/2/2018BMO Capital MarketsReiterated RatingHold$82.00High
8/2/2018Cantor FitzgeraldSet Price TargetBuy$98.00High
7/30/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$97.00 ➝ $100.00Low
7/27/2018Cantor FitzgeraldSet Price TargetBuy$98.00Low
7/13/2018Jefferies Financial GroupSet Price TargetBuy$96.00Medium
6/6/2018Cantor FitzgeraldSet Price TargetBuy$98.00Low
5/16/2018BMO Capital MarketsReiterated RatingHold$80.00Low
5/16/2018Cantor FitzgeraldReiterated RatingBuy$98.00Low
5/1/2018Cantor FitzgeraldSet Price TargetBuy$90.00Low
4/25/2018Craig HallumReiterated RatingBuy$87.00 ➝ $94.00Low
4/24/2018Cantor FitzgeraldSet Price TargetBuy$90.00Medium
4/19/2018Hilliard LyonsDowngradeNeutralLow
4/19/2018CitigroupReiterated RatingBuy ➝ Buy$85.00 ➝ $98.00Low
4/13/2018Jefferies Financial GroupReiterated RatingBuy$96.00Low
4/5/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$83.00 ➝ $89.00Low
3/19/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$70.00Low
2/26/2018Jefferies Financial GroupSet Price TargetBuy$97.00Low
2/17/2018BarclaysSet Price TargetHold$77.00Medium
2/16/2018Deutsche Bank AktiengesellschaftBoost Price TargetHold ➝ Hold$76.00 ➝ $78.00Low
2/16/2018Piper Jaffray CompaniesSet Price TargetBuy$88.00Low
2/16/2018Stifel NicolausReiterated RatingBuy ➝ Buy$84.00 ➝ $86.00Medium
2/16/2018Bank of AmericaBoost Price TargetBuy$80.00 ➝ $87.00Medium
2/15/2018Cantor FitzgeraldSet Price TargetBuy$90.00Medium
2/15/2018BMO Capital MarketsSet Price TargetHold$78.00Medium
2/15/2018CowenSet Price TargetBuy$85.00Medium
1/22/2018BMO Capital MarketsSet Price TargetHold$78.00Low
1/18/2018Piper Jaffray CompaniesReiterated RatingBuy$86.00Low
1/16/2018Jefferies Financial GroupReiterated RatingBuy$89.00High
1/11/2018Cantor FitzgeraldSet Price TargetBuy$85.00Low
1/9/2018BMO Capital MarketsBoost Price TargetPositive ➝ Market Perform$78.00Medium
1/8/2018BMO Capital MarketsReiterated RatingHoldLow
1/4/2018CitigroupUpgradeNeutral ➝ Buy$85.00Low
1/2/2018Craig HallumReiterated RatingBuy$77.00 ➝ $85.00Low
1/2/2018Cantor FitzgeraldSet Price TargetBuy$85.00Low
12/26/2017Cantor FitzgeraldSet Price TargetBuy$85.00Low
12/12/2017Cantor FitzgeraldSet Price TargetBuy$80.00Low
11/29/2017Morgan StanleyUpgradeEqual Weight ➝ Overweight$80.00Low
11/24/2017UBS GroupReiterated RatingBuy ➝ NeutralN/A
11/17/2017CowenSet Price TargetBuy$70.00 ➝ $80.00N/A
11/10/2017Jefferies Financial GroupReiterated RatingBuyN/A
11/3/2017BMO Capital MarketsBoost Price TargetMarket Perform$65.00 ➝ $70.00N/A
11/3/2017Morgan StanleyBoost Price TargetEqual Weight$61.00 ➝ $70.00N/A
11/2/2017BMO Capital MarketsReiterated RatingHold$65.00N/A
10/31/2017Cantor FitzgeraldSet Price TargetBuy$75.00N/A
10/25/2017BMO Capital MarketsSet Price TargetHold$65.00N/A
10/24/2017Cantor FitzgeraldReiterated RatingBuy$75.00N/A
10/24/2017Stifel NicolausReiterated RatingBuy$65.00N/A
9/26/2017Cantor FitzgeraldReiterated RatingBuy$75.00Low
9/6/2017Cantor FitzgeraldReiterated RatingBuy$75.00Low
9/1/2017Stifel NicolausReiterated RatingBuy$65.00Low
8/25/2017Piper Jaffray CompaniesSet Price TargetBuy$73.00Low
8/24/2017CowenSet Price TargetBuy$70.00Low
8/14/2017Cantor FitzgeraldSet Price TargetBuy$75.00Low
8/7/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$62.00Low
7/25/2017Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$65.00High
7/21/2017Stifel NicolausReiterated RatingBuy$65.00Low
7/17/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$62.00 ➝ $65.00Low
7/17/2017CowenSet Price TargetBuy$70.00Low
7/11/2017CowenSet Price TargetBuy$60.00Low
6/20/2017Hilliard LyonsInitiated CoverageBuy$77.00Low
6/16/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$75.00Low
6/13/2017BMO Capital MarketsDowngradeOutperform ➝ Market Perform$64.00 ➝ $65.00Low
5/30/2017ArgusReiterated RatingBuy$60.00 ➝ $69.00Low
5/26/2017CL KingInitiated CoverageBuy ➝ Buy$71.00Low
5/24/2017Credit Suisse GroupBoost Price TargetOutperform$61.00 ➝ $67.00Low
5/9/2017Jefferies Financial GroupBoost Price TargetBuy$65.00 ➝ $70.00Low
5/4/2017BMO Capital MarketsReiterated RatingBuy$60.00High
3/15/2017Craig HallumInitiated CoverageBuy$65.00Low
2/19/2017BMO Capital MarketsReiterated RatingOutperform$60.00N/A
2/16/2017GuggenheimBoost Price TargetBuy$60.00 ➝ $65.00N/A
2/16/2017Off Wall StreetReiterated RatingStrong Sell$35.00N/A
2/8/2017BMO Capital MarketsReiterated RatingBuy$60.00N/A
1/20/2017Jefferies Financial GroupBoost Price TargetBuy$62.00 ➝ $64.00N/A
12/23/2016GuggenheimReiterated RatingBuy$60.00N/A
12/23/2016BMO Capital MarketsReiterated RatingOutperform$59.00N/A
12/20/2016Deutsche Bank AktiengesellschaftInitiated CoverageBuy$62.00N/A
12/20/2016Jefferies Financial GroupReiterated RatingBuy$62.00N/A
12/15/2016Piper Jaffray CompaniesReiterated RatingOverweight$61.00N/A
12/15/2016CowenUpgradeMarket Perform ➝ Outperform$50.00 ➝ $60.00N/A
11/3/2016JPMorgan Chase & Co.Reiterated RatingHold$53.00N/A
10/16/2016Jefferies Financial GroupReiterated RatingBuy$63.00N/A
10/12/2016Stifel NicolausReiterated RatingBuy$58.00N/A
9/29/2016Bank of AmericaInitiated CoverageBuy$60.00N/A
9/14/2016Jefferies Financial GroupReiterated RatingBuy$60.00N/A
9/9/2016ArgusBoost Price TargetBelow Average$54.00 ➝ $58.00N/A
9/7/2016Credit Suisse GroupReiterated RatingFocus List$60.00N/A
8/23/2016Credit Suisse GroupReiterated RatingOutperform$60.00N/A
8/23/2016Jefferies Financial GroupReiterated RatingBuy$60.00N/A
8/22/2016GuggenheimReiterated RatingPositive$60.00N/A
8/4/2016Jefferies Financial GroupBoost Price TargetBuy$58.00 ➝ $60.00N/A
8/4/2016CitigroupBoost Price TargetNeutral$50.00 ➝ $53.00N/A
8/4/2016BarclaysBoost Price TargetEqual Weight$45.00 ➝ $49.00N/A
7/18/2016GuggenheimReiterated RatingBuy$60.00N/A
(Data available from 6/24/2016 forward)
Zoetis logo
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Read More

Today's Range

Now: $186.12
Low: $185.28
High: $186.55

50 Day Range

MA: $174.94
Low: $165.45
High: $186.62

52 Week Range

Now: $186.12
Low: $131.28
High: $187.32


1,271,096 shs

Average Volume

1,941,610 shs

Market Capitalization

$88.36 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Zoetis?

The following Wall Street analysts have issued research reports on Zoetis in the last twelve months: Argus, Atlantic Securities, Bank of America Co., Barclays PLC, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, Edward Jones, G.Research, Llc, Gabelli, Morgan Stanley, Raymond James, Stifel Nicolaus, Truist, Truist Financial Co., and Zacks Investment Research.
View the latest analyst ratings for ZTS.

What is the current price target for Zoetis?

12 Wall Street analysts have set twelve-month price targets for Zoetis in the last year. Their average twelve-month price target is $184.25, suggesting a possible downside of 1.0%. Barclays PLC has the highest price target set, predicting ZTS will reach $208.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $160.00 for Zoetis in the next year.
View the latest price targets for ZTS.

What is the current consensus analyst rating for Zoetis?

Zoetis currently has 6 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZTS will outperform the market and that investors should add to their positions of Zoetis.
View the latest ratings for ZTS.

What other companies compete with Zoetis?

How do I contact Zoetis' investor relations team?

Zoetis' physical mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company's listed phone number is 973-822-7000 and its investor relations email address is [email protected] The official website for Zoetis is

This Shocking Industry Set to Become a Massive $400 Billion Market
It's worth next to nothing today… But soon, this burgeoning industry could blossom into a massive $400 billion market. That's the kind of ground floor opportunity that only comes along once in a generation.